跳至主要内容
临床试验/NCT05496101
NCT05496101招募中2 期

Intraoperative Assessment of Tumour Excision Margins Using the LightPath Imaging System for Cerenkov Luminescence Imaging (CLI) Combined With Flexible Autoradiography (FAR) in Women Undergoing Breast-conserving Surgery (BCS)

King's College London2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2022年11月21日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
入组人数
60
试验地点
2
主要终点
Margin status of WLE specimens

研究概览

简要总结

This study is a prospective, single arm interventional study to evaluate the diagnostic accuracy of intraoperative Cerenkov luminescence imaging (CLI) plus flexible autoradiography (FAR) using the LightPath® Imaging System for intraoperative tumour margin assessment compared to post-operative standard-of-care histopathology in women undergoing breast-conserving surgery for breast cancer.

详细描述

The intraoperative LightPath images will be used to inform the operating surgeon about potentially detectable cancer at the margins of the excised specimen in an attempt to achieve better guided cancer surgery and complete tumour excision with clear resection margins. If a positive excision margin is detected on intraoperative LightPath® images, the operating surgeon will take a cavity shaving of the corresponding margin, provided more tissue can be taken. Subsequent LightPath® imaging of the cavity shaving will inform the operating surgeon on the margin status of the shaving. If a positive excision margin is detected on intraoperative LightPath® images, the operating surgeon will take a further cavity shave of the corresponding margin, provided more tissue can be taken.

The resection margin status of the WLE specimen and cavity shavings (if any), as assessed by LightPath CLI + FAR imaging will be compared with final histopathology results.

A positive margin on histology will be defined as

  • Invasive carcinoma: positive: <1mm; negative ≥1mm
  • Ductal carcinoma in situ (DCIS) (if present): positive: <2mm; negative ≥2mm.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • • Female subjects ≥18 years of age with a diagnosis of invasive breast cancer scheduled to undergo BCS
  • Subjects who are able to give voluntary, written informed consent to participate in this study
  • Subjects who are able to understand this study and are willing to complete all the study assessments
  • Female subjects of childbearing age must have a negative pregnancy test (by Beta human chorionic gonadotrophin (β-HCG) qualitative analysis) or must have had a history of a surgical sterilisation or must give history of no menses in the past twelve months.

排除标准

  • Subjects who have had surgery to the ipsilateral breast in the past 12 months
  • Subjects who have had radiotherapy to the ipsilateral breast
  • Subjects who have a known hypersensitivity to 18F-FDG
  • Subjects who are pregnant or lactating
  • Subjects who have an existing medical condition that would compromise their participation in the study

结局指标

主要结局

Margin status of WLE specimens

时间窗: complete surgical procedure

The resection margin status of the WLE specimen and cavity shavings (if any), as assessed by LightPath CLI + FAR imaging will be compared with final histopathology results. A positive margin on histology will be defined as * Invasive carcinoma: positive: \<1mm; negative ≥1mm * Ductal carcinoma in situ (DCIS) (if present): positive: \<2mm; negative ≥2mm. The resection margin status of the WLE specimen and cavity shavings (if any), as assessed by LightPath CLI + FAR imaging will be compared with final histopathology results. A positive margin on histology will be defined as * Invasive carcinoma: positive: \<1mm; negative ≥1mm * Ductal carcinoma in situ (DCIS) (if present): positive: \<2mm; negative ≥2mm.

次要结局

  • • Agreement between margin status of cavity shavings as determined by intraoperative CLI + FAR LightPath imaging and post-operative histopathology.(complete surgical procedure)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验